Papers - SATO Atsushi
-
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022
Yukinori Ozaki, Takamichi Yokoe, Tetsuhiro Yoshinami, Kazuki Nozawa, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano
Int J Clin Oncol 2024.3
-
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022
Keita Uchino, Shingo Tamura, Shoji Kimura, Keisuke Shigeta, Takahiro Kimura, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Yuji Miura
Int J Clin Oncol 2024.3
-
Efectiveness and safety of primary prophylaxis with G‑CSF after induction therapy for acute myeloid leukemia: a systematic review and meta‑analysis of the clinical practice guidelines for the use of G‑CSF 2022 from the Japan society of clinical oncology
Tomoya Maeda、Yuho Najima、Yutaro Kamiyama、Shinji Nakao、Yukinori Ozaki、Hiroshi Nishio、Kenji Tsuchihashi、Eiki Ichihara、Yuji Miumra、Makoto Endo、Dai Maruyama、Tatsuhiro Yoshinami1、Nobuyuki Susumu、Munetaka Takekuma、Takashi Motohashi、Mamoru Ito、Eishi Baba、Nobuaki Ochi、Toshio Kubo、Keita Uchino、Takahiro Kimura、Shinobu Tamura、Hitomi Nishimoto、Yasuhisa Kato、Atsushi Sato、Toshimi Takano、Shingo Yano
Int J Clin Oncol 2024.3
-
Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201)
Hiroo Imai, Yasuhiro Sakamoto, Shin Takahashi, Hiroyuki Shibata, Atsushi Sato, Kazunori Otsuka, Kenji Amagai, Masanobu Takahashi, Takuhiro Yamaguchi, Chikashi Ishioka
BMC Cancer 24 ( 1 ) 2024.2
-
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022
Eiki Ichihara, Nobuaki Ochi, Go Makimoto, Kenichiro Kudo, Daijiro Harada, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu , Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura , Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Toshio Kubo
Int J Clin Oncol 2024.2
-
Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study
Ryohei Kawabata, Keisho Chin, Daisuke Takahari, Hisashi Hosaka, Osamu Muto, Yoshiaki Shindo, Naoki Nagata, Hiroshi Yabusaki, Hiroshi Imamura, Shunji Endo, Tomomi Kashiwada, Masato Nakamura, Jun Hihara, Michiya Kobayashi, Tamotsu Sagawa, Soh Saito, Atsushi Sato, Takeshi Yamada, Naohiro Okano, Ken Shimada, Masashi Matsushima, Masato Kataoka, Shigemi Matsumoto, Masahiro Goto, Masahito Kotaka, Takeshi Shiraishi, Hiromichi Yamai, Fumio Nagashima, Naoki Ishizuka, Kensei Yamaguchi
Gastric Cancer 26 ( 6 ) 1020 - 1029 2023.8
-
Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy
Junichi Nakagawa， Takenori Takahata， Yu Chen， Kensuke Saito， Kosuke Kamata， Takuto Tachita，Satoru Yamashita， Keigo Saito， Kayo Ueno， Atsushi Sato， Hirotake Sakuraba， Takenori Niioka
Cancer Chemother Pharmacol 92 ( 5 ) 391 - 398 2023.8
-
アントラサイクリン系抗がん剤の血管外漏出にデクスラゾキサンを使用した4例の報告
高畑武功，佐藤 温，照井一史，中原潤一，兵頭 塁，粟津朱美，阿保恵美子，蓮井研吾，陳 豫，斎藤絢介，佐々木洸太
癌と化学療法 50 ( 4 ) 467 - 471 2023.4
-
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
Yasuyuki Kawamoto, Satoshi Yuki, Kentaro Sawada, Michio Nakamura, Osamu Muto, Susumu Sogabe, Yoshiaki Shindo, Atsushi Ishiguro, Atsushi Sato, Yasushi Tsuji, Masayoshi Dazai, Hiroyuki Okuda, Takashi Meguro, Kazuaki Harada, Mari Sekiguchi, Kazufumi Okada, Yoichi M Ito, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
Oncologist 27 ( 8 ) e642 - e649 2022.8
-
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer
Shintaro Nakano, Yasuyuki Kawamoto, Satoshi Yuki, Kazuaki Harada, Takuto Miyagishima, Susumu Sogabe, Masayoshi Dazai, Atsushi Sato, Atsushi Ishiguro, Michio Nakamura, Shinya Kajiura, Yasuo Takahashi, Miki Tateyama, Kazuteru Hatanaka, Yasushi Tsuji, Takahide Sasaki, Yoshiaki Shindo, Tomoe Kobayashi, Isao Yokota, Naoya Sakamoto, Yuh Sakata, Yoshito Komatsu
BMJ Open 12 ( 5 ) e048833 - e048833 2022.5
-
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
Yasuyuki Kawamoto, Satoshi Yuki, Takashi Meguro, Kazuteru Hatanaka, Minoru Uebayashi, Michio Nakamura, Hiroyuki Okuda, Ichiro Iwanaga, Takashi Kato, Shintaro Nakano, Atsushi Sato, Kazuaki Harada, Koji Oba, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
27 ( 5 ) 340-e374 - 340-e374 2022.5
-
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer
Ken Ito, Satoshi Yuki, Hiroshi Nakatsumi, Yasuyuki Kawamoto, Kazuaki Harada, Shintaro Nakano, Rika Saito, Takayuki Ando, Kentaro Sawada, Masataka Yagisawa, Atsushi Ishiguro, Masayoshi Dazai, Ichiro Iwanaga, Kazuteru Hatanaka, Atsushi Sato, Ryusuke Matsumoto, Yoshiaki Shindo, Miki Tateyama, Tetsuhito Muranaka, Masaki Katagiri, Isao Yokota, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
Support Care Cancer 2022.3
-
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
Denda T, Takashima A, Gamoh M, Iwanaga I, Komatsu Y, Takahashi M, Nakamura M, Ohori H, Sakashita A, Tsuda M, Kobayashi Y, Baba H, Kotake M, Ishioka C, Yamada Y, Sato A, Yuki S, Morita S, Takahashi S, Yamaguchi T, Shimada K
154 296 - 306 2021.9
-
Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report
Sasaki K, Yokota Y, Isojima T, Fujii M, Hasui K, Y Chen, Saito K, Takahata T, Kindaichi S, Sato A
Asian Pacific Society of Respirology 9 ( 7 ) 2021.9
-
Multicenter Analysis of Hand Foot Syndrome by CapeOx Therapy Using Telephone Support Program after Radical Colon Cancer Surgery
Junichi Koike, Kaoru Furushima, Shin Sasaki, Atsushi Satoh, Kazuteru Watanabe, Mitsunori Ushigome, Tomoaki Kaneko, Hiroyuki Shiokawa, Satoru Kagami, Mari Oba and Kimihiko Funahashi
74 ( 5 ) 287 - 295 2021.5
-
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C
Cancer science 112 ( 4 ) 1567 - 1578 2021.4
-
Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy.
Nakagawa J, Takahata T, Hyodo R, Chen Y, Hasui K, Sasaki K, Saito K, Ueno K, Hosoi K, Terui K, Sato A, Niioka T
Scientific reports 11 ( 1 ) 785 2021.1
-
nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
M Ueno, T Ioka, A Sato, et al.
Cancer Medicine 24 ( 9 ) 9396 - 9408 2020.10
-
A Case of Non-Resectable Pancreatic Cancer With Multiple Hepatic Metastases Treated With FOLFIRINOX Therapy and Conversion Surgery
Gan To Kagaku Ryoho 46 ( 13 ) 2551 - 2553 2019.12
-
[A Case of Non-Resectable Pancreatic Cancer with Multiple Hepatic Metastases Treated with FOLFIRINOX Therapy and Conversion Surgery].
Akaishi T, Ishido K, Kimura N, Nagase H, Odagiri T, Fujita H, Chen Y, Saito K, Takahata T, Sato A, Hakamada K
Gan to kagaku ryoho. Cancer & chemotherapy 46 ( 13 ) 2551 - 2553 2019.12